Lumit® Immunoassays: An Easier Faster Method for Analyte Detection
- Use simple, add-mix-read protocols to detect a variety of analytes
- Implement existing Lumit® assays in your lab or build your own Lumit® immunoassays
- Analyze data using examples for cytokine detection, signaling pathway analysis and FcRn binding
Summary
In Lumit® Immunoassays, antibodies (or other affinity reagents) are chemically labeled with the small and large subunits of NanoLuc® Luciferase, know as SmBiT and LgBiT, respectively. In the presence of an analyte, the two antibodies come into close proximity, allowing SmBiT and LgBiT to form an active enzyme and generate a bright luminescence signal. This homogeneous detection chemistry has several advantages, including simple, add-mix-read protocols, no requirement for sample transfer, no washes, and a broad linear dynamic range, mitigating the need for sample dilutions. Moreover, time to assay completion is <30 to <90 minutes, depending on the specific assay. In development are assays for detection of cytokines (e.g., IL-1β), metabolic targets (e.g., Insulin), FcRn binding, cellular pathway analyses (total and phospho-protein levels), as well as labeling kits to build your own Lumit® Immunoassays.
Speakers
Dan Lazar, PhD
Senior Research Scientist
Dr. Dan Lazar received his Ph.D. in biological chemistry from the University of Michigan and then completed a postdoctoral fellowship focused on cell signaling at Warner Lambert/Parke-Davis. Subsequently, he was a Team Leader and Senior Scientist at Eli Lilly within the metabolic disease drug-discovery area for well over a decade where he gained extensive experience in the development, validation and implementation of cell-based and biochemical assays for drug discovery. As a Group Leader and Senior Research Scientist at Promega, Dan and his colleagues are principally focused on delivering novel cell-based assays for the quantitative assessment of various aspects of cell health to assist academic and industrial investigators.
Martha O'Brien, PhD
Senior Research Scientist
Martha O’Brien is a Senior Research Scientist in the Assay Design Group at Promega and is currently leading assay development efforts in the area of inflammation. Martha received her PhD in biology from the University of North Carolina. Prior to joining Promega, she was a postdoctoral fellow and research associate in the Anatomy and Neurobiology Department at Washington University School of Medicine investigating the genetics of neuropeptide systems in Drosophila. As a Promega R&D scientist, she turned to mammalian systems and has developed numerous products, focusing on apoptosis and protease assays, has co-authored several articles and book chapters, and is a co-inventor on several patents.
Hicham Zegzouti, PhD
Senior Research Scientist
Dr. Hicham Zegzouti is a Senior Research Scientist in Promega Assay Design-R&D. His group develops Assay technologies to interrogate diverse enzyme activities and cellular pathways (kinases, glycosyltransferases, and other drug targets). Dr. Zegzouti received his PhD in 1997 from the National Polytechnic Institute of Toulouse, France. Prior to joining Promega, he was a postdoctoral researcher in Molecular, Cell and Developmental Biology at UC-Los Angeles studying auxin hormone signaling in an Arabidopsis plant model. His work focused on the identification and characterization of AGC kinase family and its regulation during plant development. Dr. Zegzouti has authored 14 journal articles and book chapters, co-edited a methods book and is an inventor on several patents.
Nidhi Nath, PhD
R&D Group Leader, Protein and Nucleic Acid Purification
Dr. Nath is a group leader in Protein and Nucleic Acid Purification group at Promega Corporation leading development of new tools for antibody and protein purification and functional analysis. Dr. Nath has a Ph.D in Biomedical Engineering from Indian Institute of Technology, Delhi, India.